ftInvstr
MARKSANS · Healthcare ₹327.8 -1.43% Mkt Cap ₹14875 Cr overvalued

MARKSANS

Healthcare Drug Manufacturers - General
₹327.8
-1.43% today · 30d +22.04%
as of 2026-09-04
Price · Daily Candles
AI narrative is temporarily unavailable for MARKSANS. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹841 Cr
+35.61% YoY
NET PROFIT
₹159 Cr
+173.89% YoY
OPM
27.53%
+10.62pp YoY
EPS
₹3.47
PE 29.39
Intrinsic value · DCF ₹98.77 · Margin of safety -69.9% (overvalued) · FCF yield 2.2%
◇ Sector Position
PEERPEROCE %
MARKSANS29.3920.0
GLAXO46.8657.97
RUBICON101.0127.36
PFIZER28.6424.29
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
82
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation REASONABLE 60
Growth STRONG 90
Profitability HIGH 92
Technicals NEUTRAL 63
Risk LOW 90
Key Stats
TTM PE
29.39
P/B
5.02
52W HIGH
₹345.5
OFF HIGH
-5.12%
DIV YIELD
0.28%
MKT CAP
₹14875 Cr
◉ Active Signals
MACDNeutral-1.1355
RSI(14)Bullish61.49
Street Consensus
3 analysts
₹324.33
mean target
Low ₹210.0Now ₹327.8High ₹385.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MARKSANS and at what entry.

Sign up freeSign in